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EXPERIMENTAL PROCEDURES

Antibody cloning, expression, and purification
The anti-HER2 monoclonal antibody trastuzumab in scFv-Fc format containing one Cterminal Sec residue was generated as described previously. 1 The Fc region of this construct contains the hinge-C H 2-C H 3 sequence of human IgG1, followed by a TGA codon, six His codons, a TAA codon, and a SECIS element from the 3'-UTR of the cDNA of human TXNRD1. The antibody without Sec residue was generated by removing TGA codon and SECIS element while Strep; Life Technologies) in a humidified 5% CO 2 atmosphere at 37 °C. The mammalian cell expression vectors described above were transiently transfected into HEK 293C18 cells using polyethylenimine (PEI; Polysciences). After 6-12 h of transfections, media were replaced with fresh DMEM without FBS. For antibodies with engineered Sec residues, 1 µM sodium selenite (Na 2 SeO 3 ; Sigma-Aldrich) was added to the medium. Culture supernatants were collected on days 3, 6, and 9 after transfections and filtered using 0.45-m Stericup filter units (Millipore).
The supernatants were loaded on a 1-mL recombinant Protein A column (HiTrap; GE Healthcare) connected to an ÄKTApurifier system (GE Healthcare). PBS was used for column equilibration and washing, 0.5 M acetic acid (pH 3.0) for elution, and 1 M Tris-HCl (pH 8.0) for immediate S4 neutralization. The neutralized eluate was buffer exchanged into PBS and concentrated simultaneously using 30-kDa cutoff centrifugal filter devices (Millipore). In order to separate scFv-Fc-Sec-His protein from scFv-Fc-stop protein, the purified scFv-Fc protein mixture was 10fold diluted in loading/washing buffer (500 mM NaCl and 25 mM imidazole in PBS) and loaded on a 1-mL immobilized metal ion affinity chromatography (IMAC) column (HisTrap, GE Healthcare) connected to the ÄKTApurifier system. Subsequently, the column was washed with 10 mL loading/washing buffer, and the bound scFv-Fc-Sec-His protein was eluted with elution buffer (500 mM NaCl and 500 mM imidazole in PBS). Pooled fractions were buffer exchanged into PBS and concentrated as described above. All antibodies were determined to be >95% pure by SDS-PAGE. Yields for trastuzumab scFv-FcS396C-Sec protein reached 4 mg/L compared to 20 mg/L for trastuzumab scFv-FcS396C and scFv-Fc. 
Dual antibody conjugation
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Second step. For selective conjugation at the Cys interface, a 5-fold molar excess of methylsulfone-ODA-fluorescein (2% DMSO in reaction buffer) was added to above samples.
The reactions were allowed to proceed for 1 h at RT. Unconjugated compounds were removed by using a 30-kDa cutoff centrifugal filter device. The conjugates in PBS were stored at 4 ºC for short term use and at -80 ºC in aliquots for long term use. Antibody concentrations were determined with the Bio-Rad Protein Assay, using a known concentration of an unconjugated antibody as standard. A flow cytometry-based internalization assay was performed as previously described 2 .
SDS-PAGE
Briefly, SK-BR-3 cells were incubated with 20 ng/mL of trastuzumab scFv-Fc or scFv- 
Surface plasmon resonance
Surface plasmon resonance for the measurement of trastuzumab scFv-Fc and scFv-FcS396C-Sec/biotin/ODA-fluorescein affinities to HER2 was performed on a Biacore X100 instrument using Biacore reagents and software (GE Healthcare). Recombined human HER2-Fc (R&D Systems) in 10 mM sodium acetate (pH 4.5) was immobilized on a CM5 sensor chip at a density of 1,418 resonance units (RU). Antibodies were injected at five concentrations ranging from 0.625 to 10 nM. The sensor chip was regenerated with 4.5 M MgCl 2 without loss of any binding capacity. The sensorgram data were fit to a bivalent analyte model using Biacore X100 evaluation software.
Confocal immunofluorescence microscopy
A confocal immunofluorescence microscopy-based approach was used to visualize antibody internalization. SK-BR-3 and MDA-MB-468 cells on coverslips were treated with 2 μg/mL of trastuzumab scFv-FcS396C-Sec/biotin/ODA-fluorescein at 37 ºC for 4 h. Next, noninternalized antibody was removed by washing with acidic buffer (Tris-glycine buffer, pH 2.5).
Cells were fixed with 4% (v/v) formaldehyde and permeabilized with 0.1% (v/v) Triton X-100.
Internalized antibody was revealed with Cy3-conjugated goat anti-human Fcγ F(ab') 2 fragment S8 (Jackson ImmunoResearch). Cells were counterstained with Hoechst 33342 (Sigma-Aldrich).
Visualization of internalized antibody was performed using an Olympus IX81 confocal microscope and SlideBook digital microscopy software (Intelligent Imaging Innovations).
Human plasma stability
Trastuzumab scFv-FcS396C-Sec/biotin/ODA-fluorescein at a concentration of 1.3 mg/mL was diluted 1:1 (v/v) into human plasma and incubated at 37 °C for the duration of the time course study. Time points (0, 12, 24, 48, and 72 h) were removed and stored at -80 ºC, and then SDS-PAGE and Western blotting were performed as above without DTT in sample loading buffer. A mouse anti-His mAb (Qiagen) was used as control for detection of the total antibody (conjugated and unconjugated).
Mass spectrometry
Deglycosylation was performed by incubating 100 µg antibody samples with 5 µL N-Glycosidase F (Promega) at 37 ºC overnight. MALDI-TOF mass spectra were recorded on an AB SCIEX 4800 Plus MALDI-TOF/TOF Analyzer in linear high-mass positive mode. All 
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Compounds
The synthesis of methylsulfone-ODA-fluorescein ( Figure 1B ) was described previously. 2 Biotin-ethylenediamine-iodoacetamide ( Figure 1B) was purchased from Biotium. Biotin-PEGiodoacetamide ( Figure S3A Figure S3B ). The fractions containing the iodoacetamide compound were confirmed by mass spectrometry using a AB SCIEX 4800 Plus MALDI-TOF/TOF Analyzer ( Figure S3C ), pooled together, and lyophilized using a Virtis S10 Benchtop K (Model 4KBTZL) Lyophilizer. All compounds were dissolved in DMSO at 10 mM stock concentration and stored at -80 ºC in aliquots. TABLE   Table S1 . Kinetic parameters for the interaction between antibodies and HER2-Fc as determined by surface plasmon resonance. The sensorgram data were fit to a bivalent analyte model. Figure S1 . Avidity measurements by surface plasmon resonance. Biacore X100 sensorgrams for the binding of trastuzumab scFv-Fc (A) and scFv-FcS396C-Sec/biotin/ODA-fluorescein (B) to immobilized human HER2-Fc after instantaneous background depletion. The antibodies were injected at five different concentrations ranging from 0.615 to 10 nM (bottom to top). The dashed black line marks the fitted curve. 
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